Skip to main content
Clinical Trials/JPRN-jRCTs062190020
JPRN-jRCTs062190020Completed未知

Effectiveness(performance) evaluation trial of hemodiafilter ABH-PA at pre-dilution and post-dilution on-line hemodiafiltration

OKADA Kazuyoshi0 sites8 target enrollmentStarted: October 15, 2019Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
8

Study Overview

Brief Summary

It was confirmed that hemodiafilter ABH-PA changed its removal performance depending on the amount of replacement fluid in both pre-dilution and post-dilution in HDF mode. Further, it was confirmed that the removal performance of ABH-PA tends to increase as the amount of replacement liquid increases. In addition, no significant difference was observed in the inflammatory maker level between the pre-dilution and the post-dilution.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to < 85age old (—)
Sex
All

Inclusion Criteria

  • 1) Patients on stable maintenance on-line hemodiafiltration therapy at least one month.
  • 2) Patients with capable of obtaining blood flow rate >= 280 mL/min.
  • 3) Patients who are undergoing hemodiafiltration with a hemodiafiler of membrane area >= 2.2m^2.
  • 4) Patients who are undergoing hemodiafiltration for >= 4 hours per treatment.
  • 5) Patients who are capable to participate in the study as outpatients.
  • 6) Patients capable of understanding the informed consent form.
  • 7) Patients >= 20 years and <85 years of age at the time of informed consent.

Exclusion Criteria

  • 1)Patients requiring another blood purification therapy such as peritoneal dialysis other than
  • hemodiafiltration within this study period.
  • 2)Patients with a medical history of anaphylaxis symptoms caused by polysulfone or polyvinylpyrrolidone (PVP).
  • 3)Patients who will participate in other clinical trials that may influence the results of this study within this study period.
  • 4)Patients in the opinion of the principal investigator to disqualify from participation.

Investigators

Sponsor
OKADA Kazuyoshi

Similar Trials